| Concept                      | Keywords                             | MeSH terms                   |
|------------------------------|--------------------------------------|------------------------------|
| Multimorbidity <sup>17</sup> | Co-morbidity.tw,kf                   | Comorbidity/                 |
|                              | Multimorbidity.tw,kf                 | Multiple chronic conditions/ |
|                              | Multi-morbidity.tw,kf                | Multimorbidity/              |
|                              | (Multiple adj2 (disease* or          |                              |
|                              | disorder* or condition*)).tw,kf      |                              |
|                              | Comorbidity.tw,kf                    |                              |
| Maternal                     | ((Maternal or perinatal or           | Maternal health/Pregnancy    |
| morbidity                    | peripartum or prenatal or antenatal  | complications/               |
|                              | or pregnancy or postpartum or        | Pregnancy, high risk/        |
|                              | postnatal) adj2 complication*).tw,kf | Pregnancy outcome/           |
|                              | ((Maternal or perinatal or           |                              |
|                              | peripartum or prenatal or antenatal  |                              |
|                              | or pregnancy or postpartum or        |                              |
|                              | postnatal) adj2 morbidity).tw,kf     |                              |
| Maternal                     | ((Maternal or perinatal or           | Maternal death/              |
| mortality                    | peripartum or prenatal or antenatal  | Maternal mortality/          |
|                              | or pregnancy or postpartum or        |                              |
|                              | postnatal) adj2 mortality).tw,kf     |                              |
| Perinatal health             | ((Maternal or perinatal or           | Critical care/               |
| care use                     | peripartum or prenatal or antenatal  | Health care costs/           |
|                              | or pregnancy or postpartum or        | Hospitalization/             |
|                              | postnatal) adj2 hospital*).tw,kf     | Intensive care units/        |
|                              |                                      | Length of stay/              |

## Table S1. Example of Medline search strategy

## Table S2. Study characteristics

| Study                         | Study location,<br>study period           | Study design,<br>data sources                                    | Sample size,<br>response, follow-up<br>rates   | Inclusion<br>criteria  | Multimorbidity<br>definition   | Outcome<br>definition(s)   | Confounders controlled for   |
|-------------------------------|---|--|--|--|--|--|--|
| Admon<br>2018 a <sup>22</sup> | United States,<br>2013-2014               | Cross-<br>sectional<br>study,<br>National<br>Inpatient<br>Sample | N=12,567 with ≥ 2<br>conditions<br>N=127,350 with 1<br>condition<br>N=1,368,496 with no<br>conditions<br>Response rate: NA<br>Follow-up rate: NA<br>Missing data: < 3% | All hospital<br>deliveries                                     | 2+ of chronic heart<br>disease, chronic<br>hypertension, chronic<br>kidney disease, chronic<br>liver disease, chronic<br>respiratory disease, HIV,<br>pre-existing diabetes,<br>substance use disorders<br>using ICD-9-CM codes<br>from delivery<br>hospitalizations   | Severe maternal<br>morbidity<br>(composite) or<br>mortality,<br>hospital<br>transfer, length<br>of stay, using<br>hospital<br>discharge data | Controlled for<br>age, rural<br>residence,<br>insurance payer,<br>median<br>household<br>income, hospital<br>region, obstetric<br>outcomes (in<br>sensitivity<br>analyses) |
| Admon<br>2018 b <sup>23</sup> | United States,<br>2012-2015               | Cross-<br>sectional<br>study,<br>National<br>Inpatient<br>Sample | N=55,404 with ≥ 2<br>conditions<br>N=326,852 with 1<br>condition<br>N=2,141,636 with no<br>conditions<br>Response rate: NA<br>Follow-up rate: NA<br>Missing data: < 6% | All hospital<br>deliveries                                     | 2+ of chronic heart<br>disease, chronic<br>hypertension, chronic<br>kidney disease, chronic<br>respiratory disease, HIV,<br>depression, pre-existing<br>diabetes, pulmonary<br>hypertension,<br>substance use<br>disorders, systemic<br>lupus erythematosus<br>using ICD-9-CM codes<br>from delivery<br>hospitalizations | Severe maternal<br>morbidity<br>(composite),<br>using hospital<br>discharge data   | Stratified by<br>ethnicity;<br>controlled for<br>age, rural<br>residence,<br>primary<br>insurance payer,<br>median<br>household<br>income, and<br>hospital region          |
| Bandoli<br>2017 <sup>24</sup> | United States<br>and Canada,<br>2009-2016 | Prospective<br>cohort study,<br>MotherToBaby<br>Study            | N=179 with 1 of the<br>autoimmune diseases<br>and depression<br>N=1,228 with<br>autoimmune disease<br>only<br>N=153 with   | English or<br>Spanish-<br>speaking,<br>singleton<br>livebirths | Comorbid autoimmune<br>disease (rheumatoid<br>arthritis, Crohn's<br>disease, or psoriasis)<br>and depression, using<br>self-report verified by<br>medical record review  | Preeclampsia,<br>using self-report<br>verified by<br>medical record<br>review  | Controlled for<br>age,<br>socioeconomic<br>status, race/<br>ethnicity, medical<br>comorbidities,<br>smoking, BMI,  |

| Study                            | Study location,<br>study period | Study design,<br>data sources                                    | Sample size,<br>response, follow-up<br>rates  | Inclusion<br>criteria  | Multimorbidity<br>definition  | Outcome<br>definition(s)   | Confounders<br>controlled for  |
|----------------------------------|---------------------------------|--|---|--|---|--|--|
|                                  |                                 |  | depression only<br>N=1,550 with no<br>conditions  |  |   |  | gestational age at<br>enrollment   |
|                                  |                                 |  | Response rate: NR<br>Follow-up rate: NR<br>Missing data: NR   |  |   |  |  |
| Brown<br>2020 <sup>25</sup>      | United States,<br>2016-2017     | Cross-<br>sectional<br>study,<br>National<br>Inpatient<br>Sample | N=60,718 with ≥ 3<br>comorbidities<br>N=145,131 with 2<br>comorbidities<br>N=296,185 with 1<br>comorbidity<br>N=1,480,925 with 0<br>comorbidities<br>Response rate: NA<br>Follow-up rate: NA<br>Missing data: <1% | All hospital<br>deliveries<br>with no<br>missing data  | Number of chronic<br>comorbidities, defined<br>using the 29 Elixhauser<br>comorbidity measures<br>identified by the<br>Healthcare Cost and<br>Utilization Project,<br>excluding coagulation<br>deficiency, complicated<br>hypertension,<br>congestive heart failure,<br>peripheral perivascular<br>disease, and pulmonary<br>circulation disorders<br>(which were also<br>included in outcome),<br>using hospital discharge<br>data | Severe maternal<br>morbidity<br>(composite,<br>overall and<br>excluding those<br>with blood<br>transfusion as<br>the only<br>indicator), using<br>hospital<br>discharge data | Controlled for<br>age, race/<br>ethnicity, primary<br>expected payer,<br>median<br>household<br>income, location<br>of residence,<br>delivery type |
| Czerwinski<br>2012 <sup>26</sup> | United States,<br>1996-2008     | Prospective<br>cohort study,<br>Omega Study                      | N=112 with asthma<br>and migraine<br>N=933 with 1<br>condition<br>N=2,686 with neither<br>condition<br>Response rate: 79%<br>Follow-up rate: NR<br>Missing data: < 4%   | English-<br>speaking, ≥<br>18 years,<br>prenatal care<br>< 20 weeks,<br>planning to<br>deliver at<br>term in<br>eligible<br>hospital | Comorbid asthma and<br>migraine, using self-<br>report verified by<br>medical record review   | Pregnancy-<br>induced<br>hypertension<br>and<br>preeclampsia,<br>from medical<br>records   | Controlled for<br>age, parity, race/<br>ethnicity, marital<br>status, medical<br>comorbidities,<br>smoking, BMI,<br>multifetal<br>pregnancy        |

| study period                | data sources   | Sample size,<br>response, follow-up<br>rates  | Inclusion<br>criteria  | Multimorbidity definition  | Outcome<br>definition(s)   | Confounders<br>controlled for  |
|-----------------------------|--|---|--|--|--|--|
| United States,<br>2002-2014 | Retrospective<br>cohort study,<br>Nationwide<br>Inpatient<br>Sample        | N=222 with sickle cell<br>disease and HIV<br>N=127,954 with 1<br>condition<br>N=57,198,505 with<br>neither condition<br>Response rate: NA<br>Follow-up rate: NA<br>Missing data: < 1% | All hospital<br>deliveries   | Comorbid sickle cell<br>disease and HIV, using<br>ICD-9-CM codes from<br>delivery hospitalizations   | Severe<br>preeclampsia,<br>mild<br>preeclampsia,<br>pregnancy<br>complications<br>(composite),<br>using hospital<br>discharge data   | Controlled for<br>age, income,<br>insurance status,<br>race/ethnicity,<br>geographical<br>location   |
| Canada, 2002-<br>2017       | Retrospective<br>cohort study,<br>Ontario health<br>administrative<br>data | N=43,952 with 7-32<br>ADGs<br>N=139,728 with 5-6<br>ADGs<br>N=471,959 with 3-4<br>ADGs<br>N=2,070,354 with ≤2<br>ADGs<br>Response rate: NA  | All<br>recognized<br>pregnancies<br>among<br>Ontario<br>residents  | Number of<br>comorbidities before<br>the clinical start of<br>pregnancy, expressed<br>as the total number of<br>Aggregated Diagnosis<br>Groups (ADGs) obtained<br>with the Johns Hopkins<br>Adjusted Clinical Group<br>System  | Any emergency<br>department visit<br>during<br>pregnancy or up<br>to 42 days<br>postpartum,<br>using hospital<br>discharge data  | Controlled for<br>age, parity,<br>income quintile,<br>region of<br>residence,<br>immigrant status,<br>antenatal care<br>provider   |
|                             | 2002-2014<br>Canada, 2002-   | 2002-2014 cohort study,<br>Nationwide<br>Inpatient<br>Sample<br>Canada, 2002-<br>2017 Retrospective<br>cohort study,<br>Ontario health<br>administrative                              | United States,<br>2002-2014Retrospective<br>cohort study,<br>Nationwide<br>Inpatient<br>SampleN=222 with sickle cell<br>disease and HIV<br>N=127,954 with 1<br>condition<br>SampleN=127,954 with 1<br>conditionN=57,198,505 with<br>neither conditionSampleN=57,198,505 with<br>neither conditionResponse rate: NA<br>Follow-up rate: NA<br>Missing data: < 1% | United States,<br>2002-2014Retrospective<br>cohort study,<br>Nationwide<br>Inpatient<br>SampleN=222 with sickle cell<br>disease and HIV<br>conditionAll hospital<br>deliveriesNationwide<br>Inpatient<br>SampleN=127,954 with 1<br>conditionAll hospital<br>deliveriesNationwide<br>Inpatient<br>SampleN=57,198,505 with<br>neither conditionSampleN=57,198,505 with<br>neither conditionResponse rate: NA<br>Follow-up rate: NA<br>Missing data: < 1% | United States,<br>2002-2014Retrospective<br>cohort study,<br>NationwideN=222 with sickle cell<br>disease and HIV<br>NationwideAll hospital<br>deliveriesComorbid sickle cell<br>disease and HIV, using<br>ICD-9-CM codes from<br>delivery hospitalizations2002-2014Nationwide<br>Inpatient<br>SampleN=127,954 with 1<br>conditionAll hospital<br>deliveriesComorbid sickle cell<br>disease and HIV, using<br>ICD-9-CM codes from<br>delivery hospitalizationsSampleN=57,198,505 with<br>neither conditionResponse rate: NA<br>Follow-up rate: NA<br>Missing data: < 1% | United States,<br>2002-2014Retrospective<br>cohort study,<br>Nationwide<br>Inpatient<br>SampleN=222 with sickle cell<br>disease and HIV<br>N=127,954 with 1<br>conditionAll hospital<br>deliveriesComorbid sickle cell<br>disease and HIV, using<br>ICD-9-CM codes from<br>delivery hospitalizationsSevere<br>preeclampsia,<br>mild2002-2014Nationwide<br>Inpatient<br>SampleN=57,198,505 with<br>neither conditionN=57,198,505 with<br>neither conditionSevere<br>delivery hospitalizationsSevere<br>preeclampsia,<br>mildCanada, 2002-<br>2017Retrospective<br>cohort study,<br>Ontario health<br>administrative<br>dataN=43,952 with 7-32<br>ADGsAll<br>recognized<br>pregnancies<br>amongNumber of<br>recognized<br>pregnancy, expressed<br>as the total number of<br>duringAny emergency<br>department visit<br>during<br>pregnancy or up<br>to 42 days<br>postpartum,<br>using hospital<br>discharge dataCanada, 2002-<br>2017Retrospective<br>cohort study,<br>ADGsN=43,952 with 7-32<br> |

Abbreviations: ADG = aggregated diagnosis group; NA = not applicable; NR = not reported.